Educational programs building upon the most current research and professional practice recommendations in thoracic cancer, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
IASLC 2019 World Conference on Lung Cancer: Independent satellite symposium
Chaired by Corey Langer with Enriqueta Felip, David Heigener and Myung-Ju Ahn Access the scientific summary with video highlights and faculty interviews, including take-home messages from the symposium.
08-10-2018 | Lung cancer | Scientific summary | Collection
This symposium discussed the latest in non-driver mutation lung cancer, from histologic and molecular profiling, through to current and emerging treatment options, including those for patients with refractory and aggressive disease. The objective was to discuss the challenges that this patient group presents, and the progress being made to overcome them.
This program was made possible thanks to an independent educational grant from Eli Lilly and Company.
This symposium provided practical advice for clinicians treating NSCLC in an increasingly intricate therapeutic landscape. The expert Faculty guided the audience through case studies covering the harder-to-treat squamous NSCLC patient and the increasingly complex problem of what is the best approach for adenocarcinoma patients who rapidly progress. This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company.
This symposium, held in Panama City, aimed to facilitate the management of squamous and non-squamous NSCLC. It addressed the challenges facing clinicians in the Latin-American region by placing the latest developments in advanced NSCLC into the context of treatment. The expert Faculty provided their insights into how biological knowledge can be used not only to improve treatment pathways, but to maximize outcomes by understanding different treatment approaches. This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.